1,3,5-trinitro-1,3,5-triazinane increases expression EXP 6480464 cyclonite results in increased expression of MIR27B mRNA CTD PMID:25559034 1,3,5-trinitro-1,3,5-triazinane increases expression ISO RGD:1607665 6480464 cyclonite results in increased expression of MIR27B mRNA CTD PMID:19270793 17beta-estradiol decreases expression ISO RGD:1343068 6480464 Estradiol results in decreased expression of MIR27B mRNA CTD PMID:22403704 , PMID:30328349 2,5-hexanedione increases expression EXP 6480464 2, 5-hexanedione results in increased expression of MIR27B mRNA CTD PMID:31760062 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of MIR27B mRNA CTD PMID:24472605 arsenite(3-) increases expression ISO RGD:1607665 6480464 arsenite results in increased expression of MIR27B mRNA CTD PMID:27932253 arsenous acid increases expression ISO RGD:1343068 6480464 Arsenic Trioxide results in increased expression of MIR27B mRNA CTD PMID:22072212 benzo[a]pyrene increases expression ISO RGD:1343068 6480464 Benzo(a)pyrene results in increased expression of MIR27B mRNA CTD PMID:22048643 benzo[a]pyrene decreases expression ISO RGD:1343068 6480464 Benzo(a)pyrene results in decreased expression of MIR27B mRNA CTD PMID:31515600 benzo[a]pyrene multiple interactions ISO RGD:1343068 6480464 [IL6 protein co-treated with Benzo(a)pyrene] results in decreased expression of MIR27B mRNA CTD PMID:31515600 bis(2-chloroethyl) sulfide decreases expression ISO RGD:1607665 6480464 Mustard Gas results in decreased expression of MIR27B mRNA CTD PMID:26456178 bisphenol A decreases expression ISO RGD:1343068 6480464 bisphenol A results in decreased expression of MIR27B, bisphenol A results in decreased expression of MIR27B mRNA CTD PMID:22403704 more ... bisphenol A multiple interactions ISO RGD:1343068 6480464 [bisphenol A results in decreased expression of MIR27B] which results in increased expression of FADD mRNA more ... CTD PMID:30690568 bleomycin A2 decreases expression EXP 6480464 Bleomycin results in decreased expression of MIR27B mRNA CTD PMID:25933445 bucladesine multiple interactions ISO RGD:1343068 6480464 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA CTD PMID:30328349 butanal increases expression ISO RGD:1343068 6480464 butyraldehyde results in increased expression of MIR27B mRNA CTD PMID:26079696 cadmium atom multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MIR27B mRNA CTD PMID:33652105 cadmium dichloride multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MIR27B mRNA CTD PMID:33652105 cadmium dichloride affects expression EXP 6480464 Cadmium Chloride affects the expression of MIR27B mRNA CTD PMID:35525383 cadmium dichloride multiple interactions ISO RGD:1607665 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of MIR27B mRNA CTD PMID:24080485 carbon nanotube increases expression ISO RGD:1607665 6480464 Nanotubes, Carbon results in increased expression of MIR27B mRNA CTD PMID:25926378 , PMID:32976959 carbon nanotube multiple interactions ISO RGD:1607665 6480464 Rosiglitazone inhibits the reaction [Nanotubes, Carbon results in increased expression of MIR27B mRNA] CTD PMID:32976959 chromium(6+) decreases expression ISO RGD:1343068 6480464 chromium hexavalent ion results in decreased expression of MIR27B mRNA CTD PMID:30690063 cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of MIR27B mRNA CTD PMID:24880025 cisplatin decreases expression ISO RGD:1343068 6480464 Cisplatin results in decreased expression of MIR27B mRNA CTD PMID:27392435 cisplatin decreases expression EXP 6480464 Cisplatin results in decreased expression of MIR27B mRNA CTD PMID:27397436 curcumin decreases expression ISO RGD:1343068 6480464 Curcumin results in decreased expression of MIR27B mRNA CTD PMID:29723631 DDT decreases expression ISO RGD:1343068 6480464 DDT results in decreased expression of MIR27B mRNA CTD PMID:22403704 diarsenic trioxide increases expression ISO RGD:1343068 6480464 Arsenic Trioxide results in increased expression of MIR27B mRNA CTD PMID:22072212 ferulic acid multiple interactions EXP 6480464 [resveratrol co-treated with Phytic Acid co-treated with ferulic acid co-treated with Quercetin] results in decreased expression of MIR27B mRNA CTD PMID:21203465 formaldehyde decreases expression ISO RGD:1343068 6480464 Formaldehyde results in decreased expression of MIR27B mRNA CTD PMID:21147603 fumonisin B1 decreases expression ISO RGD:1343068 6480464 fumonisin B1 results in decreased expression of MIR27B mRNA CTD PMID:24614526 , PMID:33496827 fumonisin B1 multiple interactions ISO RGD:1343068 6480464 [fumonisin B1 results in decreased expression of MIR27B mRNA] which results in increased expression of NFE2L2 mRNA more ... CTD PMID:33496827 hydrogen peroxide increases expression ISO RGD:1343068 6480464 Hydrogen Peroxide results in increased expression of MIR27B mRNA CTD PMID:26339600 isoprene decreases expression ISO RGD:1343068 6480464 isoprene analog results in decreased expression of MIR27B mRNA CTD PMID:31765140 lead diacetate multiple interactions ISO RGD:1607665 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of MIR27B mRNA CTD PMID:24080485 Licochalcone B decreases expression ISO RGD:1343068 6480464 licochalcone B results in decreased expression of MIR27B mRNA CTD PMID:33647349 mechlorethamine increases expression EXP 6480464 Mechlorethamine results in increased expression of MIR27B mRNA CTD PMID:33971176 medroxyprogesterone acetate multiple interactions ISO RGD:1343068 6480464 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA CTD PMID:30328349 methapyrilene affects expression EXP 6480464 Methapyrilene affects the expression of MIR27B mRNA CTD PMID:24863736 mono(2-ethylhexyl) phthalate decreases expression ISO RGD:1343068 6480464 mono-(2-ethylhexyl)phthalate results in decreased expression of MIR27B mRNA CTD PMID:30858031 mono(2-ethylhexyl) phthalate multiple interactions ISO RGD:1343068 6480464 MIR27B mRNA inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of PCNA mRNA] more ... CTD PMID:30858031 myo-inositol hexakisphosphate multiple interactions EXP 6480464 [resveratrol co-treated with Phytic Acid co-treated with ferulic acid co-treated with Quercetin] results in decreased expression of MIR27B mRNA CTD PMID:21203465 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of MIR27B mRNA CTD PMID:27397436 paracetamol increases expression ISO RGD:1607665 6480464 Acetaminophen results in increased expression of MIR27B mRNA CTD PMID:19246379 paracetamol increases expression ISO RGD:1343068 6480464 Acetaminophen results in increased expression of MIR27B, Acetaminophen results in increased expression of MIR27B mRNA CTD PMID:25359176 , PMID:28545106 paracetamol affects expression EXP 6480464 Acetaminophen affects the expression of MIR27B mRNA CTD PMID:24863736 PhIP multiple interactions ISO RGD:1343068 6480464 [IL6 protein co-treated with 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine] results in decreased expression of MIR27B mRNA CTD PMID:31515600 progesterone decreases expression ISO RGD:1343068 6480464 Progesterone results in decreased expression of MIR27B mRNA CTD PMID:30328349 propofol increases expression EXP 6480464 Propofol results in increased expression of MIR27B mRNA CTD PMID:26254736 quercetin multiple interactions EXP 6480464 [resveratrol co-treated with Phytic Acid co-treated with ferulic acid co-treated with Quercetin] results in decreased expression of MIR27B mRNA CTD PMID:21203465 resveratrol multiple interactions EXP 6480464 [resveratrol co-treated with Phytic Acid co-treated with ferulic acid co-treated with Quercetin] results in decreased expression of MIR27B mRNA more ... CTD PMID:21203465 , PMID:22050707 resveratrol decreases expression EXP 6480464 resveratrol results in decreased expression of MIR27B mRNA CTD PMID:21203465 , PMID:22050707 silver atom decreases expression ISO RGD:1343068 6480464 Silver results in decreased expression of MIR27B mRNA CTD PMID:26551752 silver(0) decreases expression ISO RGD:1343068 6480464 Silver results in decreased expression of MIR27B mRNA CTD PMID:26551752 sodium arsenite increases expression ISO RGD:1343068 6480464 sodium arsenite results in increased expression of MIR27B mRNA CTD PMID:27054085 sodium arsenite decreases expression ISO RGD:1343068 6480464 sodium arsenite results in decreased expression of MIR27B mRNA CTD PMID:34032870 sodium arsenite increases expression ISO RGD:1607665 6480464 sodium arsenite results in increased expression of MIR27B mRNA CTD PMID:24896083 sodium arsenite multiple interactions ISO RGD:1607665 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of MIR27B mRNA CTD PMID:24080485 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of MIR27B mRNA CTD PMID:34492290 titanium dioxide increases expression ISO RGD:1607665 6480464 titanium dioxide results in increased expression of MIR27B mRNA CTD PMID:29247641 zinc atom decreases expression EXP 6480464 Zinc deficiency results in decreased expression of MIR27B mRNA CTD PMID:22689922 zinc(0) decreases expression EXP 6480464 Zinc deficiency results in decreased expression of MIR27B mRNA CTD PMID:22689922